ARTHUR GRP
GenericsARTHUR GRP is a generic drug manufacturer focused on Infectious Disease, Cardiovascular.
ARTHUR GRP's Key Drugs
ARTHUR GRP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ARTHUR GRP's Recent FDA Approvals
New NDA/BLA approvals for ARTHUR GRP over the last two years — novel drugs only, excluding generics and label supplements.
ARTHUR GRP's Therapeutic Areas
ARTHUR GRP's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ARTHUR GRP's Top Competitors
ARTHUR GRP's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ARTHUR GRP Pipeline Snapshot
Active clinical trials for ARTHUR GRP across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2018-03-20
- Latest
- 2025-03-31
- Applications
- 5